Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1kappa type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC)[1][2].
Molecular Weight:
(144.95 kDa)
Purity:
99
CAS Number:
[2417649-97-7]
Target:
PD-1/PD-L1
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
